Results 31 to 40 of about 2,227,737 (406)

Chronic heart failure with reduced ejection fraction [PDF]

Canadian Medical Association Journal, 2014
See also page [510][1] and [www.cmaj.ca/lookup/doi/10.1503/cmaj.131742][2] Heart failure with reduced ejection fraction is a clinical syndrome of dyspnea, exercise intolerance and/or edema resulting from an impairment of ejection of blood, usually documented by a left ventricular ejection ...
Yasbanoo Moayedi, Jeremy Kobulnik
openaire   +3 more sources

Evidence-Based Medical Therapy in Patients With Heart Failure With Reduced Ejection Fraction and Chronic Kidney Disease

Circulation, 2022
Chronic kidney disease (CKD) as identified by a reduced estimated glomerular filtration rate (eGFR) is a common comorbidity in patients with heart failure with reduced ejection fraction (HFrEF).
I. E. Beldhuis, C. Lam, J. Testani, A. Voors, H. V. Van Spall, J. T. ter Maaten, K. Damman   +6 more
semanticscholar   +1 more source

Effectiveness and safety of transcatheter aortic valve replacement in elderly people with severe aortic stenosis with different types of heart failure

BMC Cardiovascular Disorders, 2023
Background Impaired left ventricular function is an independent predictor of adverse clinical outcomes in patients with aortic stenosis. The aim of this study is to evaluate the short-term changes of echocardiographic parameters, New York Heart ...
Mei Dong, Lizhen Wang, Gary Tse, Tao Dai, Lihong Wang, Zhicheng Xiao, Tong Liu, Faxin Ren   +7 more
doaj   +1 more source

Therapeutic Stalemate in Heart Failure With Preserved Ejection Fraction

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2021
The findings of randomized trials of neurohormonal modulation have been neutral in heart failure with preserved ejection fraction and consistently positive in heart failure with reduced ejection.
Rohan Samson, Thierry H. Le Jemtel
doaj   +1 more source

Empagliflozin and health-related quality of life outcomes in patients with heart failure with reduced ejection fraction: the EMPEROR-Reduced trial

European Heart Journal, 2021
Aims In this secondary analysis of the EMPEROR-Reduced trial, we sought to evaluate whether the benefits of empagliflozin varied by baseline health status and how empagliflozin impacted patient-reported outcomes in patients with heart failure with ...
J. Butler, S. Anker, G. Filippatos, M. Khan, J. Ferreira, S. Pocock, N. Giannetti, J. Januzzi, I. Piña, C. Lam, P. Ponikowski, N. Sattar, S. Verma, M. Brueckmann, W. Jamal, O. Vedin, B. Peil, C. Zeller, F. Zannad, M. Packer   +19 more
semanticscholar   +1 more source

Heart failure with mid‐range ejection fraction: pro and cons of the new classification of Heart Failure by European Society of Cardiology guidelines

ESC Heart Failure, 2020
Currently, the assessment of left ventricular ejection fraction (LVEF) is the cornerstone of the classification of patients with heart failure (HF). The mid‐range LVEF (HFmrEF) category was identified in an attempt to uncover specific characteristics of ...
Luca Branca, Marco Sbolli, Marco Metra, Marat Fudim   +3 more
doaj   +1 more source

Time to Clinical Benefit of Dapagliflozin and Significance of Prior Heart Failure Hospitalization in Patients With Heart Failure With Reduced Ejection Fraction.

JAMA cardiology, 2021
Importance Dapagliflozin has been shown to reduce the risk of cardiovascular death or worsening heart failure (HF) in patients with chronic HF and reduced ejection fraction (HFrEF).
D. Berg, P. Jhund, K. Docherty, S. Murphy, S. Verma, S. Inzucchi, L. Køber, M. Kosiborod, A. Langkilde, F. Martinez, O. Bengtsson, P. Ponikowski, M. Sjöstrand, S. Solomon, J. McMurray, M. Sabatine   +15 more
semanticscholar   +1 more source

Uric acid and sodium-glucose cotransporter-2 inhibition with empagliflozin in heart failure with reduced ejection fraction: the EMPEROR-reduced trial

European Heart Journal, 2022
Background The sodium-glucose cotransporter-2 inhibitor empagliflozin decreases the risk of cardiovascular death or hospitalization for heart failure (HF) in patients with HF with reduced ejection fraction.
W. Doehner, S. Anker, J. Butler, F. Zannad, G. Filippatos, J. Ferreira, A. Salsali, Carolyn Kaempfer, M. Brueckmann, S. Pocock, J. Januzzi, M. Packer   +11 more
semanticscholar   +1 more source

Impact of sex-specific target dose in chronic heart failure patients with reduced ejection fraction [PDF]

, 2020
Aims: A recent study suggested that women with heart failure and heart failure reduced ejection fraction might hypothetically need lower doses of angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers (= renin-angiotensin-system ...
Boer, R.A. (Rudolf) de, Brugts, J.J. (Jasper), Engelen, D.J.M. (Domien JM), Erol-Yilmaz, A. (Ayten), Hoes, A.W. (Arno), Koornstra-Wortel, H.J.J. (Hetty JJ), Linssen, G.C.M. (Gerard), Meer, P. (Peter) van der, Pronk, A.C.B. (Arjen CB), Rocca, H.-P.B.-L. (Hans-Peter Brunner-La), van Tooren, R.M. (Rob M), Veenis, J.F. (Jesse)   +11 more
core   +5 more sources

Eligibility of patients with heart failure with preserved ejection fraction for sacubitril/valsartan according to the PARAGON‐HF trial

ESC Heart Failure, 2022
Aims In the heart failure (HF) with preserved ejection fraction (HFpEF) PARAGON‐HF trial, sacubitril/valsartan vs. valsartan improved mortality/morbidity in patients with left ventricular ejection fraction (LVEF) below median (57%).
Lars H. Lund, Gianluigi Savarese, Ashwin Venkateshvaran, Lina Benson, Anna Lundberg, Erwan Donal, Jean‐Claude Daubert, Emmanuel Oger, Cecilia Linde, Camilla Hage   +9 more
doaj   +1 more source